Stock Research for ACOR

ACOR

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ACOR Stock Chart & Research Data

The ACOR chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACOR chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ACOR Due diligence Resources & Stock Charts

The ACOR stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ACOR Detailed Price Forecast - CNN Money CNN View ACOR Detailed Summary - Google Finance
Yahoo View ACOR Detailed Summary - Yahoo! Finance Zacks View ACOR Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ACOR Trends & Analysis - Trade-Ideas Barrons View ACOR Major Holders - Barrons
NASDAQ View ACOR Call Transcripts - NASDAQ Seeking View ACOR Breaking News & Analysis - Seeking Alpha
Spotlight View ACOR Annual Report - CompanySpotlight.com OTC Report View ACOR OTC Short Report - OTCShortReport.com
TradeKing View ACOR Fundamentals - TradeKing Charts View ACOR SEC Filings - Bar Chart
WSJ View Historical Prices for ACOR - The WSJ Morningstar View Performance/Total Return for ACOR - Morningstar
MarketWatch View the Analyst Estimates for ACOR - MarketWatch CNBC View the Earnings History for ACOR - CNBC
StockMarketWatch View the ACOR Earnings - StockMarketWatch MacroAxis View ACOR Buy or Sell Recommendations - MacroAxis
Bullish View the ACOR Bullish Patterns - American Bulls Short Pains View ACOR Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ACOR Stock Mentions - StockTwits PennyStocks View ACOR Stock Mentions - PennyStockTweets
Twitter View ACOR Stock Mentions - Twitter Invest Hub View ACOR Investment Forum News - Investor Hub
Yahoo View ACOR Stock Mentions - Yahoo! Message Board Seeking Alpha View ACOR Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ACOR - SECform4.com Insider Cow View Insider Transactions for ACOR - Insider Cow
CNBC View ACOR Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ACOR - OTC Markets
Yahoo View Insider Transactions for ACOR - Yahoo! Finance NASDAQ View Institutional Holdings for ACOR - NASDAQ


Stock Charts

FinViz View ACOR Stock Insight & Charts - FinViz.com StockCharts View ACOR Investment Charts - StockCharts.com
BarChart View ACOR Stock Overview & Charts - BarChart Trading View View ACOR User Generated Charts - Trading View




Latest Financial News for ACOR


Acorda First Quarter 2019 Update: Webcast/Conference Call Scheduled for May 2, 2019
Posted on Thursday April 18, 2019

Acorda Therapeutics, Inc. (ACOR) will host a conference call and webcast to report its first quarter 2019 update and financial results on Thursday, May 2 at 8:30 a.m. ET. The archived webcast will be available in the Investor Relations section of the Acorda website at www.acorda.com. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.


Acorda to Gain From Inbrija Sales and Neurological Pipeline
Posted on Thursday April 11, 2019

Acorda (ACOR) aims to boost sales with the launch of its newly FDA-approved Parkinson's disease drug, Inbrija. The company's pipeline looks promising as well.


See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
Posted on Tuesday April 09, 2019

Acorda Therapeutics Inc NASDAQ/NGS:ACORView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderately high for ACOR with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on March 28. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold ACOR had net inflows of $2.35 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.


Acorda to Present New Long-Term Data for INBRIJA™ (levodopa inhalation powder) at Academy of Managed Care Pharmacy Annual Meeting
Posted on Tuesday March 19, 2019

Acorda Therapeutics, Inc. (ACOR) will present three posters with Phase 3 data on INBRIJA at the upcoming Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting taking place March 25-28, 2019, in San Diego. INBRIJA was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2018 for intermittent treatment of OFF episodes in people with Parkinson’s taking carbidopa/levodopa.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.